An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction. (NEOPECX)

NCT01234324 Phase 2 COMPLETED

That panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) will safely decrease the frequency of pT3/T4 below that of ECX alone in subjects with locally advanced adenocarcinoma of the stomach and gastroesophageal junction.

Details

Lead sponsor	AIO-Studien-gGmbH
Phase	Phase 2
Status	COMPLETED
Enrolment	171
Start date	2010-10
Completion	2017-08

Conditions

• Stomach Neoplasms
• Gastroesophageal Junction Neoplasms

Interventions

• Epirubicin, Cisplatin, Capecitabine, Panitumumab
• Epirubicin, Cisplatin, Capecitabine

Primary outcomes

• Frequency of pT3/T4 categories after surgery — after 9 weeks treatment

Countries

Germany